Monogram Biosciences Announces Conference Call to Discuss Commercial Introduction of Trofile(TM) Assay
August 06 2007 - 7:32PM
PR Newswire (US)
SOUTH SAN FRANCISCO, Calif., Aug. 6 /PRNewswire-FirstCall/ --
Monogram Biosciences, Inc. (NASDAQ:MGRM) announced that it will
hold a conference call on Tuesday, August 7, 2007 at 10:00 a.m.
(Eastern Time) to discuss the Company's plans for commercial
introduction of the Trofile Assay after today's approval by the FDA
of Pfizer's Selzentry(TM) (maraviroc). The call will be hosted by
Mr. William D. Young, Chairman and CEO of Monogram. To participate
in the live teleconference, please call (866) 454-4204, or (913)
312-6694 for international callers, fifteen minutes before the
conference begins. Live audio of the call will be simultaneously
broadcast over the Internet and will be available to members of the
news media, investors and the general public. Following the live
broadcast, a replay of the call will also be available at (888)
203-1112 or (719) 457-0820 for international callers, through
Friday, August 17, 2007. The replay passcode is 5604341. Access to
live and archived audio of the conference call will be available by
following the appropriate links at http://www.monogrambio.com/ and
clicking on the Investor Relations link. The information provided
on the teleconference is only accurate at the time of the
conference call, and Monogram will take no responsibility for
providing updated information except as required by law. About
Monogram Biosciences, Inc. Monogram is advancing individualized
medicine by discovering, developing and marketing innovative
products to guide and improve treatment of serious infectious
diseases and cancer. The Company's products are designed to help
doctors optimize treatment regimens for their patients that lead to
better outcomes and reduced costs. The Company's technology is also
being used by numerous biopharmaceutical companies to develop new
and improved antiviral therapeutics and vaccines as well as
targeted cancer therapeutics. More information about the Company
and its technology can be found on its web site at
http://www.monogrambio.com/. contacts: Alfred G. Merriweather
Jeremiah Hall Chief Financial Officer Feinstein Kean Healthcare
Tel: 650 624-4576 Tel: 415 677-2700 amerriweather@ jeremiah.hall@
monogrambio.com fkhealth.com DATASOURCE: Monogram Biosciences, Inc.
CONTACT: Alfred G. Merriweather, Chief Financial Officer of
Monogram Biosciences, Inc., +1-650-624-4576, ; or Jeremiah Hall,
Feinstein Kean Healthcare, +1-415-677-2700, , for Monogram
Biosciences, Inc. Web site: http://www.monogrambio.com/
Copyright
Monogram Technologies (NASDAQ:MGRM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Monogram Technologies (NASDAQ:MGRM)
Historical Stock Chart
From Jul 2023 to Jul 2024